QSAR studies of quinidine inhibition of CYP2D6

被引：0
|
作者：
Hutzler, JM [1 ]
Wienkers, LC [1 ]
机构：
[1] Pharmacia Corp, Global Drug Metab, Kalamazoo, MI 49007 USA
来源：
DRUG METABOLISM REVIEWS | 2002年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
343
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [31] Time dependent inhibition of CYP2D6 by fenfluramine and norfenfluramine
    Chen, Weichao G.
    Ortiz, Alvaro
    Usmani, Khawja A.
    Palamar, Safet
    Cerny, Matthew
    Smith, Brian
    Sadeque, Abu
    DRUG METABOLISM REVIEWS, 2006, 38 : 126 - 126
  • [32] More data for the CYP2D6 hypothesis?:: The in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly
    García-Parajuá, P
    de Ugarte, L
    Baca, E
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (01) : 111 - 112
  • [33] INHIBITION OF CYP2D6 BY BUPROPION IN HEALTHY VOLUNTEERS.
    Duong, A.
    Gufford, B.
    Liu, S.
    Benson, E.
    Lu, J.
    Stoughton, C.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S71 - S71
  • [34] DOSE DEPENDENT CYP2D6 INHIBITION BY BUPROPION AND LEVOMEPROMAZINE
    Haslemo, T.
    Arnestad, M.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 6 - 7
  • [35] In vitro inhibition of CYP2D6 activity by fenfluramine.
    Marcucci, K
    Gotschall, R
    Kearns, GL
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 142 - 142
  • [36] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [37] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [38] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [39] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [40] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
12345